Hypermethylation of p16 and p15 genes and RB protein expression in acute leukemia

Leukemia Research

Volumn 24, Issue 1, 2000, Pages 39-46

  Guo, Shu Xia ^a   Taki, Tomohiko ^a   Ohnishi, Hiroaki ^a   Piao, Hui Ying ^a   Tabuchi, Ken ^a   Bessho, Fumio ^a   Hanada, Ryoji ^b   Yanagisawa, Masayoshi ^a   Hayashi, Yasuhide ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b SAITAMA CHILDREN'S MEDICAL CENTER   (Japan)

Author keywords

Acute leukemia; Cyclin D1; Methylation; p15; p16; RB

Indexed keywords

ONCOPROTEIN; PROTEIN P15; PROTEIN P16;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CELL CULTURE; GENE DELETION; GENE INACTIVATION; GENE LOCUS; HUMAN; HUMAN CELL; METHYLATION; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACUTE DISEASE; CARRIER PROTEINS; CELL CYCLE PROTEINS; CPG ISLANDS; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DNA, NEOPLASM; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, P16; GENES, RETINOBLASTOMA; HUMANS; LEUKEMIA, B-CELL, ACUTE; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LEUKEMIA, MYELOID; LEUKEMIA, T-CELL, ACUTE; LOSS OF HETEROZYGOSITY; MOLECULAR PROBE TECHNIQUES; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; RETINOBLASTOMA PROTEIN; SEQUENCE DELETION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0033991683     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(99)00158-7     Document Type: Article

References (45)

1. INK4B is a potential effector of TGF-G-β-induced cell cycle. Nature. 371:1994;257-261.
2. Kamb A., Gruis N.A., Weaver-Feldhaus J., Liu Q., Harshman K., Tautigian S.V. et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 264:1994;436.
3. Nobori T., Miura K., Wu D.J., Lois A., Takabayashi K., Carson D.A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 368:1994;753.
4. Serrano M., Hannon G.J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 366:1993;704.
5. Carins P., Mao L., Merlo A., Lee D.J., Schwab D., Eby Y. et al. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science. 265:1994;415.
6. INK4B) display frequent homozygous deletions in primary cells from T-but not from B-cell lineage acute lymphoblastic leukemia. Blood. 84:1994;4038.
7. Achille I., Maria F.F., Brigida C., Fulvio D.R. High frequency of homozygous deletion of CDK4I gene in childhood acute lymphoblastic leukemia. Brit. J. Haematol. 91:1995;647.
8. Fizzotti M., Cimino G., Pisegna S., Alimena G., Quartarone C., Mandelli F. et al. Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood. 85:1995;2685.
9. INK4b/MTS2 in pediatric acute lymphoblastic leukemia. Blood. 85:1995;2321.
10. Ohnishi H., Kawamura M., Ida K., Sheng X.M., Hanada R., Nobori T. et al. Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. Blood. 86:1995;1269.
11. Kees U.R., Burton P.R., Baker D.L. Homozygous deletion of the p16/MTS1 gene in pediatric acute lymphoblastic leukemia is associated with unfavorable clinical outcome. Blood. 89:1997;4161.
12. Caldas C., Hahn S.A., da Costa L.T., Redston M.S., Schutte M., Seymour A.B. et al. Frequent somatic mutations and homozygous deletion of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet. 8:1994;27.
13. Ogawa S., Hirano N., Sato N., Takahashi T., Hangaishi A., Tanaka K. et al. Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias. Blood. 84:1994;2431.
14. Klangby U., Okan I., Magnusson K.P., Wendland M., Lind P., Wiman K.G. p16/INK4a and p15 /INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma. Blood. 91:1998;1680.
15. Takita J., Hayashi Y., Kohno T., Shiseki M., Yamaguchi N., Hanada R., Yamamoto K., Yokota J. Deletion map of chromosome 9 and p16 (CDKN2A) gene alterations in neuroblastoma. Cancer Res. 57:1997;907.
16. Gonzalez-Zulueta M., Bender C.M., Yang A.S., Nguyen T., Beart R.W., Van Tornout J.M., Jones P.A. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 55:1995;4531.
17. Herman J.G., Merlo A., Mao L., Lapidus R.G., Issa J.P., Davidson N.E., Sidransky D., Baylin S.B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55:1995;4525.
18. Merlo A., Herman J.G., Mao L., Lee D.J., Gabrielson E., Burger P.C., Baylin S.B., Sidransky D. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2 /MTS1 in human cancers. Nat. Med. 1:1995;686.
19. Costello J.F., Berger M.S., Huang H.S., Cavenee W.K. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res. 56:1996;2405.
20. Lo K.W., Cheung S.T., van Hasselt A., Tsang Y.S., Mak K.F., Chung Y.F. et al. Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res. 56:1996;2721.
21. Reed A.L., Califano J., Cairns P., Westra W.H., Jones R.M., Koch W. et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res. 56:1996;3630.
22. Herman J.G., Latif F., Weng Y., Lerman M.I., Zbar B., Liu S. et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. USA. 91:1994;9700.
23. Batova A., Diccianni M.B., Yu J.C., Nobori T., Link M.P., Pullen J., Yu A.L. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. Cancer Res. 57:1997;832.
24. INK4A characterize the major types of hematological malignancies. Cancer Res. 57:1997;837.
25. Ng M.H.L., Chung Y.F., Lo K.W., Wickham N.W.R., Lee J.C.K., Huang D.P. Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood. 89:1997;2500.
26. Sherr C.J. Mammalian G1 cyclins. Cell. 73:1990;1059.
27. Hunter T., Pines J. Cyclin and cancer II: cyclin D and CDK inhibitors come of age. Cell. 79:1994;573.
28. Bartkova J., Lukas J., Guldberg P., Alsner J., Kirkin A.F., Zeuthen J., Bartek J. The p16-Cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res. 56:1996;5475.
29. Rozenblum E., Schutte M., Goggins M., Hahn S.A., Panzer S., Zuhurak M. et al. Tumor suppressive pathways in pancreatic carcinoma. Cancer Res. 57:1997;1731.
30. Kawamura M., Kikuchi A., Kobayashi S., Hanada R., Yamamoto K., Horibe K. et al. Mutations of the p53 and ras genes in childhood t(1; 19)-acute lymphoblastic leukemia. Blood. 85:1995;2546.
31. Ohnishi H., Hanada R., Horibe K., Hongo T., Kawamura M., Naritaka S. et al. Homozygous deletion of p16/MTS1 and p15/MTS2 genes are frequent in t(1;19)-negative but not in t(1;19)-positive B-precursor acute lymphoblastic leukemia (ALL) in childhood. Leukemia. 10:1996;1104.
32. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., Sultan C. Proposals for the classification of the acute leukemias. French-American-British (FAB) co-operative group. Brit. J. Haematol. 33:1976;451.
33. Taki T., Sako M., Tsuchida M., Hayashi Y. The t (11;16)(q23;p13) translocation in myelodysplastic syndrome fuses the MLL gene to the CBP gene. Blood. 89:1997;3945.
34. Ohnishi H., Guo S.X., Ida K., Taki T., Naritaka S., Bessho F. Alterations of p16 and p15 genes in acute leukemia with MLL gene rearrangements and their correlation with clinical features. Leukemia. 11:1997;2120.
35. Taki T., Hayashi Y., Taniwaki M., Seto M., Ueda R., Hanada R. et al. Fusion of the MLL gene with two different genes, AF-6 and AF-5α, by a complex translocation involving chromosomes 5, 6, 8 and 11 in infant leukemia. Oncogene. 13:1996;2121.
36. Ritter M., de Kant E., Neubauer A. Detection of DNA methylation in the calcitonin gene in human leukemias using differential polymerase chain reaction. Leukemia. 9:1995;915.
37. Jiang W., Zhang Y.J., Kahn S.M., Hollstein M.C., Santella R.M., Lu S.H. et al. Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc. Natl. Acad. Sci. USA. 90:1993;9026.
38. He J., Allen J.R., Collins V.P., Allalunis-Turner M.J., Godbout R., Day R.S., James III C.D. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res. 54:1994;5804.
39. INK4 protein is restricted to the subset of lung cancer lines that retains wild type RB. Oncogene. 9:1994;3375.
40. Schmidt E.E., Ichimura K., Reifenberger G., Collins V.P. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res. 54:1994;6321.
41. INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene. 13:1996;1065.
42. INK4 and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity. Cancer Res. 56:1996;5557.
43. INK4 expression in resected non-small lung tumors. Cancer Res. 56:1996;3415.
44. INK4B1. Cancer Res. 56:1996;722.
45. Stone S., Dayananth P., Jiang P., Weaver-Geldhous J.M., Tavtigian S.V., Cannon-Albright L., Kamb A. Genomic structure, expression and mutational analysis of the p15 (MTS2) gene. Oncogene. 11:1995;987.